These case studies are headquartered in Massachusetts (Boston, Cambridge, Watertown, and similar). Use each company page for program detail, and use ClinicalTrials.gov links to verify current sponsor-registered studies.
Listings are curated case studies on Clari, not a complete directory of the cluster or of all public issuers. Pipeline text is for product demonstration; verify on ClinicalTrials.gov and official filings. Not medical or investment advice.
Watertown, MA, USA
Kymera Therapeutics is a clinical-stage biopharmaceutical company pioneering targeted protein degradation (TPD) to develop a new generation of small-molecule therapies for immune-inflammatory and oncology diseases. Using its proprietary Pegasus™ platform, Kymera designs bifunctional degrader molecules that use the cell's own proteasome machinery to selectively eliminate disease-causing proteins, including historically undruggable targets such as transcription factors.
Cambridge, MA, USA
Lila Sciences is building the world's first scientific superintelligence platform and fully autonomous labs for life, chemical, and materials sciences. Founded in Flagship Pioneering's labs in 2023 and unveiled in March 2025, the company combines proprietary AI foundation models with robotic AI Science Factories that autonomously generate hypotheses, design experiments, run them, and learn from results in real time.
Boston, MA, USA
Vertex Pharmaceuticals is a global biotechnology company focused on discovering, developing, and producing transformative medicines for people with serious diseases. Vertex dominates the cystic fibrosis market with five approved CFTR modulators (including Trikafta and ALYFTREK) and is diversifying into pain (JOURNAVX), gene editing (CASGEVY with CRISPR Therapeutics), cell therapy (zimislecel for type 1 diabetes), kidney disease (povetacicept for IgAN, inaxaplin for APOL1), and neuromuscular disease (VX-670 for myotonic dystrophy).
A compact map of how Clari triangulates companies, conditions, and modalities for the Boston and Cambridge corridor. The TPD matrix is a limited sponsor set. Meeting and agent context uses a wider peer list; verify any claim on registries and filings.
IL-4/IL-13 axis, atopic and allergic disease, and oral alternatives to biologics. Degraders and induced-proximity stories often cite STAT6, IRAK4, and similar targets.
Breast, prostate, and other cancers where TPD and glue programs compete on depth of target suppression. CDK2, ER, and AR narratives appear across local sponsors.
Large Boston anchors run registry-heavy programs. Useful as comparators for trial design, enrollment, and label discussions.
Transcription factors and scaffolds historically hard for occupancy-driven chemistry. TPD and glue are a defining local technical story.
Cambridge and Boston host platform companies combining foundation models, robotics, and partner-facing discovery. Overlaps informatics and emerging intel.
Deeper protein profiles: UniProt and ChEMBL-backed pages with Kymera program tie-ins where available.
See the full sortable view: TPD competitive landscape. Arvinas, Vividion, and other matrix sponsors sit outside the Boston filter above.
Often referenced next to the matrix set for TPD in Kendall and Watertown:
A sample of public Greater Boston / Cambridge / Watertown sponsors: disease threads and modality or target language. Not a directory and not trial-accurate. Use trials search and each sponsor for verification.
| Company | Local hub | Therapy areas | Modalities / targets |
|---|---|---|---|
| Aera Therapeutics | Cambridge, MA (Technology Square area) | genetic and serious disease (delivery) | endogenous and engineered delivery, AI-enabled discovery (public site) |
| Alltrna | Cambridge, MA (Flagship) | broad, platform-stage | tRNA or engineered tRNA biology · stoppable codon / translation themes |
| Alnylam Pharmaceuticals | Kendall Square, Cambridge | genetic · ATTR amyloidosis · hepatic and systemic disease | siRNA (RNAi) · TTR-directed programs |
| Amgen (Cambridge site) | Binney Street, Cambridge | oncology · inflammation · cardiovascular (portfolio-wide) | mAbs, bispecifics, standard large-molecule R&D (site in cluster) |
| Ankyra Therapeutics | Cambridge, MA | solid tumor · immuno-oncology | cytokine-anchored immunotherapy · IL-12 pathway programs |
| Beam Therapeutics | Cambridge, MA | sickle / beta-hemoglobinopathies · genetic disease | base editing · LNP delivery |
| Biogen | Cambridge (HQ in region) | neurology · MS · Alzheimer disease and neurodegeneration | recombinant biologics · ASO / antisense (historical and partnered) |
| Compass Therapeutics | Boston area | solid tumor · tumor microenvironment | antibody and bispecific mAbs to TME targets |
| Cugene | Boston, MA | oncology · autoimmunity | TIL-engaging bispecifics (public labels) · CUG family molecules |
| Foghorn Therapeutics | Cambridge, MA (Flagship ecosystem) | oncology · transcriptional regulation | chromatin regulation · BRM / mSWI/SNF complex (public focus) |
| Intellia Therapeutics | Cambridge, MA | in vivo genetic medicine · ATTR and oncology · rare disease | CRISPR/Cas9 in vivo (public pipeline themes) |
| iTeos Therapeutics | Watertown and Greater Boston | solid tumor · hematology | TIGIT pathway (public pipeline) · adenosine / tumor environment |
| Kymera Therapeutics | Watertown, MA | immunology · oncology | TPD/PROTAC · molecular glue · STAT6 · IRAK4 · IRF5 |
| Lila Sciences | Cambridge, MA (Alewife / IQHQ) | platform R&D; partner and internal therapeutic programs | autonomous lab · AI foundation models for protein and chemistry |
| Moderna | Cambridge (Greater Boston operations) | infectious disease · cancer · rare disease | mRNA · LNP delivery |
| MOMA Therapeutics | Cambridge, MA | oncology · genetic and rare | molecular glues and degraders to transporter / enzyme targets |
| Sana Biotechnology | Cambridge, MA | cell therapy · oncology · CNS and systemic | hypoimmune allogeneic cells (public narrative) |
| Sanofi (Cambridge presence) | Cambridge, MA (regional R&D and partnerships) | vaccine · oncology · immunology (global mix) | mAb and vaccine platforms, partner molecules |
| Vertex Pharmaceuticals | Boston, MA | cystic fibrosis · acute pain · sickle cell and beta-thalassemia (franchise mix) | CFTR modulators · NaV1.8 and non-opioid pain (public labels) |